COMPARISON
EvidenceFlow vs RevMan for Systematic Reviews
Last reviewed September 14, 2026
RevMan (Review Manager) is Cochrane's official software for writing and analyzing systematic reviews, and it is the required tool for producing an actual Cochrane review - Cochrane authors are required to use it. Its strength is the opposite of Rayyan's or Covidence's: RevMan is built for structured data entry, Cochrane's RoB 2 risk-of-bias tool, and meta-analysis with forest plots, but it is not a citation screening tool - reviewers typically screen titles and abstracts elsewhere (often Covidence) and bring selected studies and extracted data into RevMan for the write-up and statistics. EvidenceFlow covers both halves of that split in one workspace: screening through PRISMA, then straight into meta-analysis, without a separate screening tool feeding a separate analysis tool.
Feature comparison
| Feature | EvidenceFlow | RevMan |
|---|---|---|
| Title/abstract & full-text screening | Yes, built in | Not a core feature - typically done in a separate tool |
| Blind dual-reviewer screening | Yes, configurable reviewer count per stage | N/A - no screening module |
| Data extraction workflow | Yes, incl. clinical + omics fields, AI auto-fill (paid) | Structured tables for entering already-extracted study data |
| Risk-of-bias assessment | Basic fields in extraction (randomization, blinding, attrition, overall judgment) - not a structured domain-by-domain tool | Yes - Cochrane's RoB 2 tool, built in with algorithmic judgment suggestions |
| PRISMA 2020 flow diagram | Yes, generated automatically from your own screening decisions | Yes, incl. the updated-review template - built from data you enter manually, since RevMan doesn't track screening itself |
| Built-in meta-analysis (pooled effects, forest/funnel plots) | Yes - fixed/random effects, Mantel-Haenszel, Peto | Yes - this is RevMan's core purpose, the standard for Cochrane meta-analyses |
| Required for official Cochrane reviews | No | Yes - Cochrane authors are required to use it |
Source for RevMan's column: www.cochrane.org/products-and-services/review-writing-software
Who each tool fits best
Consider EvidenceFlow if
- You want screening and meta-analysis in the same workspace, on the same dataset, instead of screening in one tool and analyzing in another.
- You're not producing an official Cochrane review, so RevMan isn't a requirement for you.
- Your review includes genomics/omics data alongside clinical outcomes.
Consider RevMan if
- You're producing an actual Cochrane review - RevMan is required, not optional, for that.
- You specifically need Cochrane's RoB 2 tool with its algorithmic risk-of-bias judgments.
- You already have a separate screening tool and just need best-in-class meta-analysis and review-writing software for the data it produces.
Feature availability, limits, and pricing vary by plan and can change - this is a starting point for your own evaluation, not a substitute for it.
Workflow comparison
The two tools sit on different halves of the same workflow. RevMan expects you to arrive with your studies already selected and your data already extracted elsewhere, then takes you through structured data entry, RoB 2 assessment, and meta-analysis with forest plots - producing (and, for Cochrane reviews, requiring) the final review document itself. EvidenceFlow starts a step earlier: import → screening → dual review → extraction → PRISMA → analysis → export happens on the same dataset in one workspace, with no handoff between a screening tool and an analysis tool.
Pricing
EvidenceFlow
Free: import, screening, extraction, meta-analysis, and PRISMA reporting - no review limit, no seat limit.
₹399/month: adds AI-assisted screening suggestions, extraction auto-fill, and AI manuscript drafting.
RevMan
Free for Cochrane authors working on an actual Cochrane review.
Paid annual subscription for non-Cochrane individual use, with discounted rates for students, academics, Cochrane members, and Research4Life countries.
Paid per-seat licensing for organizations.
RevMan pricing source: www.cochrane.org/revman-individuals (checked September 14, 2026). Confirm current pricing directly with RevMan before deciding.
FAQ
Is EvidenceFlow an alternative to RevMan?
For the meta-analysis and PRISMA parts, yes. For an actual Cochrane review, no - Cochrane requires RevMan specifically, and EvidenceFlow doesn't produce a Cochrane-format review document. For a non-Cochrane systematic review, EvidenceFlow additionally covers screening and dual review, which RevMan doesn't do at all.
Does EvidenceFlow generate PRISMA diagrams the same way RevMan does?
The output looks similar, but the source differs: RevMan's diagram is built from data you type in manually, since it doesn't track screening. EvidenceFlow's diagram is generated automatically from your team's actual screening decisions as they happen.
Can I do Cochrane-style meta-analysis in EvidenceFlow?
EvidenceFlow supports fixed and random-effects models, Mantel-Haenszel and Peto pooling, and forest/funnel plots. It is not a Cochrane-endorsed tool and doesn't produce a Cochrane-format review document, so it isn't a substitute for RevMan on an actual Cochrane review.
Which tool should a review team choose?
If you're authoring a Cochrane review, RevMan is required regardless of what else you use for screening. If you're running an independent (non-Cochrane) systematic review and want screening through meta-analysis without switching tools, EvidenceFlow covers both ends of that workflow. Feature sets and pricing on both platforms change - check each provider's current documentation before deciding.
Core import, screening, extraction, meta-analysis, and PRISMA reporting are free with no subscription or seat limits. AI-assisted screening, extraction auto-fill, and manuscript drafting are an optional paid upgrade.